List of Genosyl drug patents
Genosyl is owned by Vero Biotech.
Genosyl contains Nitric Oxide.
Genosyl has a total of 22 drug patents out of which 1 drug patent has expired.
Expired drug patents of Genosyl are:
- US6758214
Genosyl was authorised for market use on 20 December, 2019.
Genosyl is available in gas;inhalation dosage forms.
Genosyl can be used as a method of delivering nitric oxide to a patient, a method for delivering nitric oxide to a patient with pulmonary hypertension or hypoxia.
The generics of Genosyl are possible to be released after 12 February, 2036.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6758214 | VERO BIOTECH | Simple nitric oxide generator for ambulatory and/or bedside inhaled no treatment |
Feb, 2022
(1 year, 25 days ago) | |
| US11383059 | VERO BIOTECH | Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) |
Aug, 2025
(2 years from now) | |
| US8609028 | VERO BIOTECH | Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) |
Aug, 2025
(2 years from now) | |
| US9522249 | VERO BIOTECH | Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) |
Aug, 2025
(2 years from now) | |
| US8821801 | VERO BIOTECH | Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) |
Aug, 2025
(2 years from now) | |
| US9956373 | VERO BIOTECH | Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) |
Aug, 2025
(2 years from now) | |
| US11291793 | VERO BIOTECH | Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) |
Aug, 2025
(2 years from now) | |
| US8226916 | VERO BIOTECH | Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) |
Aug, 2025
(2 years from now) | |
| US10124142 | VERO BIOTECH | Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) |
Aug, 2025
(2 years from now) | |
| US10814092 | VERO BIOTECH | Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) |
Oct, 2025
(2 years from now) | |
| US8057742 | VERO BIOTECH | Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) |
Jan, 2026
(2 years from now) | |
| US7947227 | VERO BIOTECH | Kit for the conversion of nitrogen dioxide (NO2) to nitric oxide (NO) |
Oct, 2026
(3 years from now) | |
| US7618594 | VERO BIOTECH | Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) |
Oct, 2026
(3 years from now) | |
| US7560076 | VERO BIOTECH | Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) |
Apr, 2027
(4 years from now) | |
| US9701538 | VERO BIOTECH | Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) |
Jan, 2029
(5 years from now) | |
| US9604028 | VERO BIOTECH | Systems and devices for generating nitric oxide |
Aug, 2029
(6 years from now) | |
| US10926054 | VERO BIOTECH | Systems and devices for generating nitric oxide |
Aug, 2029
(6 years from now) | |
| US8944049 | VERO BIOTECH | Systems and devices for generating nitric oxide |
Aug, 2029
(6 years from now) | |
| US11103669 | VERO BIOTECH | Nitric oxide therapies |
Jun, 2030
(7 years from now) | |
| US8607785 | VERO BIOTECH | Systems and devices for generating nitric oxide |
Jul, 2030
(7 years from now) | |
| US10737051 | VERO BIOTECH | Nitrogen dioxide storage device |
Oct, 2035
(12 years from now) | |
| US10213572 | VERO BIOTECH | Nitrogen dioxide storage cassette |
Feb, 2036
(12 years from now) | |
Drugs and Companies using NITRIC OXIDE ingredient
Market Authorisation Date: 20 December, 2019
Treatment: A method of delivering nitric oxide to a patient; A method for delivering nitric oxide to a patient with pulmonary hypertension or hypoxia
Dosage: GAS;INHALATION
GENOSYL family patents
55
United States
12
Japan
8
Australia
7
European Union
6
Canada
Genosyl is owned by Vero Biotech Inc.
Genosyl contains Nitric Oxide.
Genosyl has a total of 1 drug patent out of which 0 drug patents have expired.
Genosyl was authorised for market use on 20 December, 2019.
Genosyl is available in gas;inhalation dosage forms.
The generics of Genosyl are possible to be released after 21 September, 2029.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11511252 | VERO BIOTECH INC | Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) |
Sep, 2029
(6 years from now) | |
Drugs and Companies using NITRIC OXIDE ingredient
Market Authorisation Date: 20 December, 2019
Treatment: NA
Dosage: GAS;INHALATION
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic